Using darolutamide in advanced prostate cancer: How I Do It

Area of Science:

• Oncology
• Pharmacology

Background:

• Prostate cancer treatment has evolved with new androgen receptor pathway inhibitors.
• Androgen deprivation therapy (ADT) is a cornerstone, but resistance necessitates novel therapies.
• Darolutamide represents a newer option for castration-resistant non-metastatic prostate cancer (nmCRPC).

Purpose of the Study:

• To review the efficacy and application of darolutamide in treating nmCRPC.
• To compare darolutamide with other available androgen receptor pathway inhibitors.
• To highlight darolutamide as the most recent FDA-approved agent in its class.

Main Methods:

• Review of clinical trial data and FDA approval information for darolutamide.
• Analysis of studies evaluating androgen receptor pathway inhibitors in nmCRPC.
• Focus on metastasis-free survival (MFS) and median survival (MS) outcomes.

Main Results:

• Darolutamide, when combined with ADT, has demonstrated prolonged MFS and MS.
• It is one of three advanced androgen receptor pathway blockers now available for nmCRPC.
• Darolutamide offers a new therapeutic avenue for patients with rising PSA despite castrate testosterone levels.

Conclusions:

• Darolutamide is a valuable addition to the treatment landscape for nmCRPC.
• The availability of agents like darolutamide enhances therapeutic options beyond traditional ADT.
• Further research and clinical experience will continue to define the role of darolutamide.